Barrett’s Oesophagus
Keywords:
MedicineDownloads
Download data is not yet available.
References
1. Aldulaimi D, Jankowski J. Barrett’s oesophagus: an overview of the molecular biology. Dis Esophagus 1999; 12(3):177-80.
2. Watson A. Barrett’s oesophagus – 50 years on. Br J Surg 2000; 87(5):529-31.
3. Kumar V, Cotran RS. Basic Pathology, W.B. Saunders Company, 6th ed (USA). 1997.
4. Sampliner, RE. Practice guidelines on the diag- nosis, surveillance, and therapy of Barrett’s oesoph- agus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93(7):1028-31.
5. Attwood SE, Barlow AP, Norris TK, et al. Barrett’s oesophagus: effect of anti-reflux surgery on symptom control and development of complica- tions. Br J Surg 1992; 79(10):1050-3.
6. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk fac-
tor for esophageal adenocarcinoma. N Engl J Med 1999; 340(11):825-31.
7. McDonald ML, Trastek VF, Allen MS, et al. Barrett’s esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996; 111(6):1135-40.
8. Stein HJ, Kauer WK, Feussner H. Bile reflux in benign and malignant Barrett’s oesophagus: effect of medical acid suppression and Nissen fundoplica- tion. J Gastrointest Surg 1998; 2(4):333-41.
9. Sharma P. An update on strategies for eradication for Barrett’s mucosa. Am J Med 2001; 111(8a):147S-52S.
10. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treat- ment of inflammation and cancer. J Clin Invest 2001; 107(2):135-41.
2. Watson A. Barrett’s oesophagus – 50 years on. Br J Surg 2000; 87(5):529-31.
3. Kumar V, Cotran RS. Basic Pathology, W.B. Saunders Company, 6th ed (USA). 1997.
4. Sampliner, RE. Practice guidelines on the diag- nosis, surveillance, and therapy of Barrett’s oesoph- agus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93(7):1028-31.
5. Attwood SE, Barlow AP, Norris TK, et al. Barrett’s oesophagus: effect of anti-reflux surgery on symptom control and development of complica- tions. Br J Surg 1992; 79(10):1050-3.
6. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk fac-
tor for esophageal adenocarcinoma. N Engl J Med 1999; 340(11):825-31.
7. McDonald ML, Trastek VF, Allen MS, et al. Barrett’s esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996; 111(6):1135-40.
8. Stein HJ, Kauer WK, Feussner H. Bile reflux in benign and malignant Barrett’s oesophagus: effect of medical acid suppression and Nissen fundoplica- tion. J Gastrointest Surg 1998; 2(4):333-41.
9. Sharma P. An update on strategies for eradication for Barrett’s mucosa. Am J Med 2001; 111(8a):147S-52S.
10. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treat- ment of inflammation and cancer. J Clin Invest 2001; 107(2):135-41.
Downloads
Published
2002-01-01
How to Cite
Dureja, P. (2002). Barrett’s Oesophagus. Trinity Student Medical Journal , 3(1), Page 27–29. Retrieved from https://ojs.tchpc.tcd.ie/index.php/tsmj/article/view/1912
Issue
Section
Reviews
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
